Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US
2015-03-26 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month. For further information Media: Mette Kruse Danielsen +45 3079 3883 [email protected] Ken Inchausti (US) +1 609 514 8316 [email protected] Investors: Kasper Roseeuw Poulsen +45 3079 4303 [email protected] Melanie Raouzeos +45 3075 3479 [email protected] Daniel Bohsen +45 3079 6376 [email protected] Frank Daniel Mersebach (US) +1 609 235 8567 [email protected] Company Announcement No 23 / 2015
The release as fetched from its publisher. novonordisk.com ↗